

Dear members of the ELN,

how do you want to be informed about changes on the ELN website? To answer this question ELIC asked all ELN members to participate in a survey dealing with this issue. By the end of May the survey was completed. We would like to thank all of you who filled in the questionnaire. Happy to say that this newsletter is your favourite source of information!

To learn more about the role of social networks in terms of information, about recent updates on the ELN website, and new studies in the European Leukemia Trial Registry (ELTR) please have a look at the topics below.

We hope you will enjoy reading.

Kind regards,

European Leukemia Information Center - ELIC

■ **Survey: Social networks - The results**

Since the annual symposium of the European LeukemiaNet earlier this year, members of the ELN were asked to comment on their usage of social networks. The purpose of the survey was to find out how to best keep you, as an ELN member, updated regarding news and innovations on the website and, in consequence, whether there is a need for an online presence of the ELN in a social network. Until the end of May, over 60 participants from all over Europe completed the questionnaire. Though half of the respondents are member of a social network only a minority would like to receive news via this source. ▶ [more details on the survey](#)

■ **Update of WP participants**

On a half-yearly basis the contact data of active participants of every workpackage are updated on the website. The current lists as well as short overviews of the respective lead participants are now online. Please find these lists including the participant's organization, nationality and e-mail address in the section "contact" of every workpackage. ▶ [contact ELIC](#)

■ **ELN recommendations**

The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects. A collection of the ELN guidelines and recommendations developed since 2006 including a review of their impact on health care is now available. ▶ [collection of ELN guidelines and recommendations](#)

■ **Schedule of the WP meetings at the 17th Congress of EHA**

From June 14 to 17 the 17th Congress of the European Hematology Association takes place in Amsterdam. On June 14 the ELN workpackages will meet at Amsterdam RAI, Europaplein 22, 1078 GZ, Amsterdam. ▶ [schedule of the WP meetings](#)

■ **New trials in the ELTR**

AMLSG 16-10 Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication

MDS Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects,

Biomarkers II Myelodysplastic Syndrome and Secondary Disorders of Haematopoiesis